Senseonics Holdings, Inc.

Senseonics Holdings, Inc. is a medical technology company that specializes in developing and commercializing continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. Their products, Eversense and Eversense XL, are implantable CGM systems that measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for up to six months. Senseonics Holdings, Inc. has an extensive network of distributors and strategic fulfillment partners to serve healthcare providers and patients. Furthermore, the company has a collaboration agreement with the University Hospitals Accountable Care Organization.

Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland and is a publicly traded company on the New York Stock Exchange under the symbol SENS. The company is led by CEO Tim Goodnow and CFO Robert Farra. Senseonics has a strong commitment to developing innovative technologies to help people with diabetes better manage their condition. The company is dedicated to providing reliable and accurate glucose monitoring solutions that are easy to use and convenient. In addition, Senseonics is working on developing new products to expand its product portfolio and provide more options for people with diabetes.